1 – 23 of 23
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells
(
- Contribution to journal › Article
- 2018
-
Mark
CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
(
- Contribution to journal › Article
-
Mark
Interleukin 4 induces apoptosis of acute myeloid leukemia cells in a Stat6 dependent manner
(
- Contribution to journal › Article
-
Mark
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI) : a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
(
- Contribution to journal › Article
- 2017
-
Mark
Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells
(
- Contribution to journal › Article
-
Mark
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
(
- Contribution to journal › Article
- 2016
-
Mark
IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models
(
- Contribution to journal › Article
-
Mark
Leukemic stem cell quantification in newly diagnosed chronic myeloid leukemia patients predicts response to nilotinib therapy
(
- Contribution to journal › Article
- 2015
-
Mark
IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome.
(
- Contribution to journal › Article
-
Mark
Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.
(
- Contribution to journal › Article
-
Mark
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
(
- Contribution to journal › Article
- 2014
-
Mark
RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib.
(
- Contribution to journal › Letter
-
Mark
Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells.
(
- Contribution to journal › Article
- 2013
-
Mark
Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients
(
- Contribution to journal › Article
-
Mark
Lentiviral gene transfer of TCIRG1 into peripheral blood CD34(+) cells restores osteoclast function in infantile malignant osteopetrosis.
(
- Contribution to journal › Article
-
Mark
Selective killing of candidate AML stem cells by antibody targeting of IL1RAP.
(
- Contribution to journal › Article
- 2010
-
Mark
The Proportion of Ph+CD34(+)CD38(neg) Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI Therapy Data From a Randomized Phase II NordCML006 Study
(
- Contribution to journal › Published meeting abstract
-
Mark
Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice
(
- Contribution to journal › Article
-
Mark
Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.
(
- Contribution to journal › Article
-
Mark
Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
(
- Contribution to journal › Article
- 2009
-
Mark
Expression of P190 and P210 BCR/ABL1 in normal human CD34(+) cells induces similar gene expression profiles and results in a STAT5-dependent expansion of the erythroid lineage
(
- Contribution to journal › Article
- 2007
-
Mark
Fusion gene-mediated truncation of RUNX1 as a potential mechanism underlying disease progression in the 8p11 myeloproliferative syndrome.
(
- Contribution to journal › Article
-
Mark
Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells
(
- Contribution to journal › Article